Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...

If you have obesity, losing even a little weight helps not only improve your overall health, but also prevent liver issues ...

If you have diabetes, taking steps to manage it can help prevent related health issues, including MASH. Here’s what to know ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s ...

Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Metabolic dysfunction-associated steatohepatitis (MASH) is often referred to as a “silent disease,” as it typically shows no signs of symptoms in early stages. But it can come with certain ...